

Panama

Population 2015

3.9 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.24 (0.22–0.25)	6.1 (5.6–6.5)
Mortality (HIV+TB only)	0.039 (<0.01–0.14)	1 (0.03–3.5)
Incidence (includes HIV+TB)	2 (1.5–2.5)	50 (38–63)
Incidence (HIV+TB only)	0.23 (0.17–0.29)	5.7 (4.3–7.3)
Incidence (MDR/RR-TB)**	0.089 (0.055–0.12)	2.3 (1.4–3.1)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.083 (0.044–0.12)	0.59 (0.3–0.87)	0.67 (0.35–0.99)
Males	0.079 (0.05–0.11)	1.2 (0.91–1.5)	1.3 (0.96–1.6)
Total	0.16 (0.11–0.21)	1.8 (1.5–2.1)	2 (1.5–2.5)

TB case notifications, 2015

Total cases notified	1 744
Total new and relapse	1 646
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	84%
- % pulmonary	83%
- % bacteriologically confirmed among pulmonary	62%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	84% (67–110)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.14 (0.1–0.2)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	198	14%
- on antiretroviral therapy	184	93%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			63 (41–85)
Estimated % of TB cases with MDR/RR-TB	3% (1.5–4.6)	12% (6.9–17)	
% notified tested for rifampicin resistance	20%	32%	650
MDR/RR-TB cases tested for resistance to second-line drugs			9
Laboratory-confirmed cases		MDR/RR-TB: 34, XDR-TB: 1	
Patients started on treatment ****		MDR/RR-TB: 34, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	79%	1 483
Previously treated cases, excluding relapse, registered in 2014	49%	97
HIV-positive TB cases, all types, registered in 2014	68%	178
MDR/RR-TB cases started on second-line treatment in 2013	50%	4
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2016

National TB budget (US\$ millions)	3
Funding source: 62% domestic, 26% international, 12% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse


— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB

Total budget (US\$ millions)



— Unfunded

— Funded internationally

— Funded domestically